全文获取类型
收费全文 | 5948篇 |
免费 | 428篇 |
国内免费 | 115篇 |
专业分类
耳鼻咽喉 | 84篇 |
儿科学 | 60篇 |
妇产科学 | 83篇 |
基础医学 | 959篇 |
口腔科学 | 33篇 |
临床医学 | 438篇 |
内科学 | 1399篇 |
皮肤病学 | 236篇 |
神经病学 | 357篇 |
特种医学 | 591篇 |
外科学 | 997篇 |
综合类 | 23篇 |
一般理论 | 2篇 |
预防医学 | 120篇 |
眼科学 | 165篇 |
药学 | 454篇 |
中国医学 | 74篇 |
肿瘤学 | 416篇 |
出版年
2024年 | 4篇 |
2023年 | 43篇 |
2022年 | 133篇 |
2021年 | 210篇 |
2020年 | 109篇 |
2019年 | 182篇 |
2018年 | 207篇 |
2017年 | 196篇 |
2016年 | 289篇 |
2015年 | 353篇 |
2014年 | 458篇 |
2013年 | 478篇 |
2012年 | 616篇 |
2011年 | 631篇 |
2010年 | 411篇 |
2009年 | 341篇 |
2008年 | 356篇 |
2007年 | 333篇 |
2006年 | 280篇 |
2005年 | 254篇 |
2004年 | 160篇 |
2003年 | 152篇 |
2002年 | 126篇 |
2001年 | 22篇 |
2000年 | 25篇 |
1999年 | 19篇 |
1998年 | 19篇 |
1997年 | 14篇 |
1996年 | 8篇 |
1995年 | 10篇 |
1994年 | 6篇 |
1993年 | 9篇 |
1992年 | 4篇 |
1991年 | 5篇 |
1990年 | 3篇 |
1989年 | 4篇 |
1988年 | 4篇 |
1987年 | 6篇 |
1985年 | 3篇 |
1981年 | 1篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1974年 | 2篇 |
1966年 | 1篇 |
1965年 | 1篇 |
1963年 | 1篇 |
排序方式: 共有6491条查询结果,搜索用时 31 毫秒
1.
2.
3.
Clinical clues for differential diagnosis between verruca plana and verruca plana‐like seborrheic keratosis 下载免费PDF全文
Won‐Jeong Kim Won‐Ku Lee Margaret Song Hoon‐Soo Kim Hyun‐Chang Ko Byung‐Soo Kim Moon‐Bum Kim 《The Journal of dermatology》2015,42(4):373-377
Sometimes the clinical differentiation between verruca plana (VP) and VP‐like seborrheic keratosis (SK) could be challenged. However, there have been no studies on this issue to date. The aim of this study was to elucidate clinical and dermoscopic differences between these two diseases, and also to suggest a diagnostic algorithm of VP and VP‐like SK without skin biopsy. The patients who had lesions clinically considered as VP or VP‐like SK were the target of our study. We took clinical and dermoscopic photos with informed consent and conducted a questionnaire. All patients had their diagnoses confirmed by biopsy. Thirty‐three patients were enrolled in our study. Seventeen patients were finally diagnosed with VP (51.5%) and 16 patients with VP‐like SK (48.5%). In clinical findings, VP‐like SK showed significantly more scattered distribution than VP (P = 0.039), which exhibited more clustered or grouped distribution (P = 0.039). In dermoscopic findings, brain‐like appearance was more commonly observed in VP‐like SK (P = 0.003) whereas VP showed more red dots or globular vessels (P = 0.017) and even‐colored light brown to yellow patch (P < 0.001). Sex, onset age, the size of each lesion, location, color and shape showed no significant differences between them (P > 0.05). Based on our results, we suggest a diagnostic algorithm using Koebner's phenomenon, dermoscopic findings, distribution of each lesion and biopsy for multiple VP‐like lesions in adults, and we think it will be a very useful diagnostic tool in daily clinical dermatological practice. 相似文献
4.
Three‐Dimensional Echocardiographic Evaluation of Mitral Apparatus during Preload Manipulation in Patients with Hypertrophic Cardiomyopathy 下载免费PDF全文
Hyemoon Chung M.D. Ji Hyun Yoon M.D. Young Won Yoon M.D. Ph.D. Ji Young Chung B.N. Jung‐Joon Cha M.D. Jong‐Youn Kim M.D. Ph.D. Pil‐Ki Min M.D. Ph.D. Byoung‐Kwon Lee M.D. Ph.D. Bum‐Kee Hong M.D. Ph.D. Se‐Joong Rim M.D. Ph.D. Hyuck Moon Kwon M.D. Eui‐Young Choi M.D. Ph.D. 《Echocardiography (Mount Kisco, N.Y.)》2015,32(8):1261-1269
5.
Choe Seong Wook MD Cho Wan Ik MD Lee Chang Kyun MD † Seo Seong Jun MD 《Dermatologic surgery》2005,31(5):502-508
BACKGROUND: Masseteric muscle hypertrophy is an uncommon dition represented as a swelling of the masseter muscle. Recent reports have demonstrated the successful use of botulinum in the treatment of masseteric hypertrophy. OBJECTIVE: This study was a prospective trial to evaluate the effectiveness of botulinum toxin type A (Botox) in the treatment of masseteric muscle hypertrophy according to doses of 10, 20, and 30 U. MATERIALS AND METHODS: Twenty-two patients were referred to the dermatologic clinic for the management of masseteric muscle hypertrophy. Ultrasonographic measurements of the thickness of the masseter muscle were performed, and clinical photographs were taken before treatment and 1, 2, 3, 4, 6, and 9 months after the treatment. RESULTS. The median values of percentage reduction of muscle mass were 10.3%, 16.5%, 23.7%, 24.7%, 21.6%, 16.5% in the 10 U group; 11.9%, 18.8%, 24.8%, 27.7%, 26.7%, and 21.8% in the 20 U group; and 12.0%, 19.4%, 25.0%, 27.8%, 37.8%, and 24.1% in the 30 U group. CONCLUSION. The adequate dose of botulinum toxin type A for treatment of masseteric muscle hypertrophy should be above 20 U. The effect of botulinum toxin type A is maintained for at least 9 months as the treatment of masseteric muscle hypertrophy. 相似文献
6.
7.
Kwang Wook Ko 《Pediatric nephrology (Berlin, Germany)》1992,6(2):197-200
Based on clinical and pathological features a typical case of haemorrhagic fever with renal syndrome passes through five phases: (1) febrile phase, (2) hypotensive phase, (3) oliguric phase, (4) diuretic phase and (5) convalescent phase. The major manifestations are fever, pain in the back and abdomen, flushed face, prostration, proteinuria, purpura and haemorrhage and acute renal failure. Selective right auricular haemorrhage, marked congestion and haemorrhage in the renal medulla and necrosis of the anterior lobe of the pituitary gland are the three prominent pathological findings. The clinical severity depends upon the causative agents, namely Hantaan virus, Seoul virus and the European form in that order. Specific serological diagnosis of haemorrhagic fever with renal syndrome is made by demonstrating a rise in titre of specific immunofluorescent antibody against Hantaan and related viruses. The management is supportive, based on an understanding of the pathophysiology of the disease. 相似文献
8.
Hyun Chul Kim Sang Woo Nam Yong Keun Cho Hey Jin Jeong Se In Kim Seong Hun Kim Chul Min An In Hee Kim Sang Wook Kim Seung Ok Lee Soo Teik Lee 《Taehan Sohwagi Hakhoe chi》2006,47(3):233-237
Although adenocarcinoma is a well known complication of chronic inflammatory bowel disease, primary gastrointestinal lymphoma occurring in Crohn's disease is rare. A 40-year-old man with 10 year-history of Crohn's disease had multiple longitudinal ulcerative lesions on descending colon in follow-up colonoscopic examination. Microscopic examination of proximal descending colon revealed peripheral T cell lymphoma and other site of the descending colon was consistent with Crohn's disease. The patient reached complete remission of malignant lymphoma after three cycles of combined chemotherapy. He has been well for 10 months with sulfasalazine maintenance therapy but was admitted to the hospital due to spontaneous bowel perforation of ascending colon. Right hemicolectomy was done, but the patient died of post-surgical recurrent mesenteric abscess and sepsis. To the best of our knowledge, this is the first case of Non-Hodgkin's lymphoma complicating Crohn's disease in Korea which was confirmed by immunohistochemical studies. 相似文献
9.
Bum Soon Choi Mi Jung Shin Suk Joon Shin Young Soo Kim Yeong Jin Choi Yong-Soo Kim In Sung Moon Suk Young Kim Yong Bok Koh Byung Kee Bang Chul Woo Yang 《American journal of transplantation》2005,5(6):1354-1360
We report here our 10-year experience of a biopsy performed at day 14 after transplantation in 304 patients with stable graft function. The factors that may have influenced subclinical rejection were analyzed according to histology. The incidence of subclinical rejection was 13.2%. Addition of mycophenolate mofetile (MMF) as a primary immunosuppressant significantly decreased the incidence of subclinical rejection compared with patients without such treatment (odds ratio, 0.23; p < 0.05). On the other hand, HLA-DR antigen mismatch (odds ratio, 2.39) and unrelated donor (odds ratio, 2.10) were also significantly associated with decreased subclinical rejection (p < 0.05). The incidence of acute rejection in patients with normal findings was lower than in those with borderline changes or subclinical rejection (0.23 +/- 0.05 vs. 0.48 +/- 0.07 and 0.60 +/- 0.11, respectively; p < 0.05). The graft survival rates in patients with subclinical rejection were lower than in patients with normal or borderline changes at 1 (88.4% vs. 97.9% and 99.1%; p < 0.05), 5 (77.8% vs. 96.2% and 95.9%; p < 0.05) and 10 (62.3% vs. 96.2% and 93.7%; p < 0.05) years. Thus, a protocol biopsy performed on day 14 after transplantation is useful for predicting graft survival. Triple therapy including MMF, related donor and HLA-DR antigen match are important factors for reducing subclinical rejection in living-donor renal transplantation. 相似文献
10.
Youn Kyung Kee Sang Youb Han Duk-Hee Kang Jung Woo Noh Kyung Hwan Jeong Gheun-Ho Kim Yang Wook Kim Beom Seok Kim 《Yonsei medical journal》2021,62(1):41
PurposeOral adsorbents delay disease progression and improve uremic symptoms in patients with chronic kidney disease (CKD). DW-7202 is a newly developed oral adsorbent with high adsorptive selectivity for uremic toxins. We evaluated patient preference for and adherence to DW-7202 versus AST-120 therapy and compared treatment efficacy and safety in patients with pre-dialysis CKD.Materials and MethodsA seven-center, randomized, open-label, two-way crossover, active-controlled, phase IV clinical trial was conducted. Patients with stable CKD were randomly assigned to receive DW-7202 (capsule type) or AST-120 (granule type) for 12 weeks. The groups then switched to the other adsorbent and took it for the next 12 weeks. Patient preference was the primary outcome. Secondary outcomes included changes in estimated glomerular filtration rate (eGFR) and serum creatinine, cystatin C, and indoxyl sulfate (IS) levels.ResultsSignificantly more patients preferred DW-7202 than AST-120 (p<0.001). Patient adherence improved after switching from AST-120 to DW-7202; there was no apparent change in adherence after switching from DW-7202 to AST-120. Changes in eGFR and serum creatinine, cystatin C, and IS levels were not significantly different according to adsorbent type. There was also no significant difference in the incidences of adverse events during treatment with DW-7202 and AST-120.ConclusionDW-7202 can be considered as an alternative to AST-120 in patients who cannot tolerate or show poor adherence to granule type adsorbents. Further studies to evaluate factors affecting patient preferences and improved adherence are warranted (Clinical trial registration No. ). NCT02681952相似文献